Akero Therapeutics (AKRO.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec3

Akero Therapeutics Inc. Acquisition Proposal by Novo Nordisk Approved by Shareholders

15:43

Nov13

Canaccord Genuity analyst maintains Akero Therapeutics' hold rating

12:07

Nov8

Akero Therapeutics released FY2025 9 Months earnings on November 7 (EST), actual revenue USD 0, actual EPS USD -2.7565

04:00

Akero Therapeutics released FY2025 Q3 earnings on November 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9946 (forecast USD -0.934)

04:00

Oct11

Novo Nordisk Plans to Acquire Akero Therapeutics for up to $5.2 Billion

17:52

Oct10

Canaccord Genuity Downgrades Akero Therapeutics to Hold

15:56

Schedules & Filings

Schedules

Filings

Nov7

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -81.57 M, EPS -0.9946

Aug8

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -70.51 M, EPS -0.8627

May12

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -70.73 M, EPS -0.8991

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change